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Tumor hypoxia is one main biological factor that drives resistance to chemotherapy
and radiotherapy. To develop a novel strategy for overcoming hypoxia-induced therapy
resistance, we examined the anti-neoplastic activity of the reactive oxygen donor dihy-
droartemisinin (DHA) in human colon cancer cell lines in normoxia and severe hypoxia. In
addition, we analyzed the involvement of the intrinsic apoptosis pathway for DHA-mediated
cytotoxicity in HCT116 cells in short-term and long-term in vitro assays. When applied at
lower concentrations (≤25µM), DHA induced apoptosis in Colo205, HCT15, and HCT116
cells, whereas necrotic cell death was increased when cells were treated with higher DHA
concentrations (50µM). However, no preference for DHA-induced apoptosis or necrosis
could be detected between the treatment under normoxic or hypoxic conditions. More-
over, DHA potently reduced clonogenic survival of HCT116 cells in normoxia and hypoxia.
Treatment of HCT116 cells with 25µM DHA resulted in activation of Bax under normoxic
and hypoxic conditions. Interestingly, cytochrome c release from the mitochondria and
caspase-activation were observed only under normoxic conditions, whereas, under hypoxic
conditions DHA induced a caspase-independent apoptosis-like cell death. However, under
both conditions, generation of reactive oxygen species was an important mediator of DHA-
induced toxicity. Further molecular analysis suggests that DHA-mediated cell death involves
different sets of pro-apoptotic Bcl-2 family members. The pronounced cytotoxic activity of
DHA in severe hypoxia as well as normoxia offers new perspectives for targeting the
hypoxic tumor cell fraction to improve treatment outcome for cancer patients.
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INTRODUCTION
Tumor cell resistance to classical chemotherapy and radiotherapy
remains a major obstacle in the treatment of solid human tumors
(1). Genetic or epigenetic alterations in the tumor cells that affect
cellular death and survival signaling can allow the tumor cells to
escape the cytotoxic action of standard genotoxic therapies and
molecularly targeted agents. Moreover, specific conditions within
the tumor microenvironment and the intimate dialog between
tumor cells and their surrounding stroma by soluble growth- and
survival-promoting factors provide a multitude of mechanisms for
therapy resistance. Therefore, current research activities focus on
the identification of drugs that are active under adverse environ-
mental conditions to counteract environment-mediated resistance
to therapies.
Tumor hypoxia is a common characteristic of solid human
tumors and is mostly associated with poor prognosis (2). Tumor
Abbreviations: Acc, N -acetylcysteine; CCCP, protonophore carbonyl cyanide m-
chlorophenylhydrazone; DHA, dihydroartemisinin; ∆Ψm, mitochondrial trans-
membrane potential; Hx, hypoxia; LC3B, light chain 3B; Nx, normoxia;
PARP, poly (ADP-ribose) polymerase; PE, plating efficiency; ROS, reactive oxy-
gen species; TMRE, tetramethylrhodamine ethyl ester perchlorate; zVAD-fmk,
benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone.
hypoxia plays a central role in tumor progression and is one main
biological factor that drives therapy resistance at multiple levels:
reduced availability of molecular oxygen during acute hypoxia
reduces the burst of reactive oxygen species (ROS) induced by
genotoxic treatments, e.g., radiotherapy, and thus hampers the
manifestation of DNA-damage and the generation of pro-death
signals. Moreover, acute hypoxia also profoundly reorganizes
cell signaling to increase the death threshold [overview in Ref.
(3)]. Finally, chronic intermittent tumor hypoxia promotes selec-
tion of hypoxia-tolerant cells that are characterized by dimin-
ished apoptotic potential, increased therapy resistance, and worse
prognosis (4–6).
At present, researchers follow diverse approaches to overcome
hypoxia-mediated therapy resistance: (i) reduce the hypoxic frac-
tion of the tumor by increasing the blood oxygen tension, (ii)
specifically kill hypoxic cells by using bioreductive drugs, and (iii)
reduce the tolerance of hypoxic cells by using signal transduction
inhibitors targeting pathways that are essential for the survival of
hypoxic cells (2, 7).
Here, we propose a novel strategy to overcome therapy resis-
tance under conditions of acute hypoxia by using the cyclic
endoperoxide dihydroartemisinin (DHA). DHA belongs to a
family of compounds derived from the natural sesquiterpene
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lactone artemisinin (Coartem®/Riamet®) that are known to gen-
erate ROS-like superoxide anions and hydroxyl radicals as well
as carbon-centered radicals upon activation of their endoper-
oxide bridge in the presence of ferrous iron (8). Artemisinin
and DHA are already in clinical use for antimalaria treatment
(9). However, both drugs also exert potent anti-neoplastic effects
on human tumor cells in preclinical in vitro and in vivo inves-
tigations (10–12). Earlier studies revealed that the generation
of ROS and carbon-centered radicals is critical for the toxic
effects of artemisinin and derivatives on malaria parasites (13,
14). These reactive molecules also contribute to the potent anti-
cancer activity of these compounds through alkylation of essential
proteins and induction of oxidative damage to membrane lipids
and DNA and subsequent ROS-dependent apoptosis that includes
the activation of pro-apoptotic Bcl-2 family member Bax, and
caspase-activation (11, 15, 16).
Though anti-neoplastic activity of artemisinin and derivatives
is well-documented for standard treatment conditions in nor-
moxia, the potential of these drugs to kill cancer cells under
conditions of acute hypoxia and the involved molecular path-
ways have not yet been studied. On the basis of their potential to
generate ROS and further reactive molecular species, we hypoth-
esized that treatment with compounds of the Artemisinin drug
family may be a promising approach to efficiently attack hypoxic
cancer cells and overcome therapy resistance induced by acute
hypoxia. To verify our hypothesis,we compared the anti-neoplastic
activity of DHA under normoxic and hypoxic conditions using
three different colorectal cancer cell lines as experimental model.
We demonstrate for the first time that DHA is a hypoxia-active
drug that efficiently kills colon cancer cells even in presence of
very low oxygen levels. When treated at lower DHA concentra-
tions (≤25µM), colon cancer cells mainly underwent apopto-
sis, whereas necrosis was increased when higher doses of DHA
(50µM) were applied.
Further molecular analysis of DHA-mediated cytotoxicity in
HCT116 cells revealed that DHA induced the canonical mito-
chondrial apoptosis pathway that includes the activation of
Bax, cytochrome c release from mitochondria into the cytosol,
caspase-activation, dissipation of the mitochondrial transmem-
brane potential (∆Ψm) and DNA-fragmentation. Although Bax-
activation occurred to similar extent when HCT116 cells were
treated under normoxic conditions, release of cytochrome c
and caspase-activation were almost abrogated. However, a high
amount of cells with fragmented or condensed DNA was observed
even in the absence of caspase-activation suggesting the induc-
tion of caspase-independent apoptotic cell death by DHA in
severely hypoxic cancer cells. Moreover, under both conditions
DHA-induced ROS production mediated the cytotoxic effect
since blocking the ROS production resulted in reduced DNA-
fragmentation. In addition, hypoxic HCT116 cells induced a
different set of regulatory BH3-only proteins in response to
DHA compared to normoxic cells suggesting that different
BH3-only proteins might contribute to the canonical and non-
canonical apoptosis in normoxia and hypoxia by inhibiting anti-
apoptotic Bcl-2 family members and facilitating the activation of
the Bax.
MATERIALS AND METHODS
CHEMICALS AND DRUGS
Dihydroartemisinin [(3,5,6,8,9,10,12R,12aR)-decahydro-3,6,9-
trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-
ol, C15H24O5)] and propidium iodide (PI) were obtained
from Sigma-Aldrich (Deisenhofen, Germany). Hoechst 33342
was purchased from Calbiochem (Bad Soden, Germany). The
pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(OMe)-
fluoromethylketone (zVAD-fmk) was obtained from Bachem
(Bubendorf, Switzerland). Tetramethylrhodamine ethyl ester per-
chlorate (TMRE) and dihydroethidium (DHE) were from Molec-
ular Probes (MoBiTec, Goettingen, Germany).
Antibodies specific for full length and cleaved poly (ADP-
ribose) polymerase (PARP), caspase-3, light chain 3B (LC3B),
Bax, Bak, Bcl-xL, and Puma were obtained from Cell Signal-
ing (Frankfurt, Germany). Bcl-2 antibody was purchased from
Santa Cruz Biotechnology (Heidelberg, Germany), Bim antibody
was purchased from Epitomics (Biomol, Hamburg, Germany).
The antibody specifically recognizing the active conformation of
Bax (Bax NT) was from Upstate (Hamburg, Germany). More-
over, we used antibodies specific for Noxa (Calbiochem, Darm-
stadt, Germany), cytochrome c (Pharmingen, Hamburg, Ger-
many), or β-actin (Sigma-Aldrich, Deisenhofen, Germany) as
well as HRP-conjugated and Cy2-conjugated secondary antibodies
(Amersham-Biosciences, Freiburg, Germany).
All other chemicals and drugs were from Sigma-Aldrich if not
otherwise specified.
CELL CULTURE
Colon cancer cell lines HCT15, Colo205, and HCT116 were
obtained from ATCC (Bethesda, MD, USA). Morphology and phe-
notype of the distinct cell lines were routinely tested before and
during data acquisition.
Cells were grown in RPMI 1640 medium supplemented with
10% (v/v) fetal calf serum (Gibco Life Technologies, Eggenstein,
Germany) and maintained in a humidified incubator at 37°C and
5% CO2 (normoxic conditions). Hypoxic cells were grown in a
humidified hypoxia work station (In vivo 400,Ruskinn Technology
Ltd., IUL Instruments GmbH, Königswinter, Germany) at 37°C,
0.2% O2, and 5% CO2.
DRUG TREATMENT
Cells were treated 24 h after seeding with 0–50µM DHA. For
treatment under hypoxic conditions, cells were transferred to the
hypoxic chamber 2 h before drug treatment. For all experiments,
0.1% ethanol was used as solvent control.
QUANTIFICATION OF CELL VIABILITY AND CELL PROLIFERATION
The number of living cells was determined upon staining of the
cells with the vital dye trypan blue. For this, cells were harvested
with Trypsin-EDTA, re-suspended in fresh medium, diluted with
trypan blue, and counted employing a Neubauer chamber.
In addition, metabolic activity of the cells was determined
as an indirect measure of cell viability using the WST-1 pro-
liferation assay according to the manufacturer’s instructions
(Roche Applied Science, Mannheim, Germany). Reduction of the
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water-soluble tetrazolium salt WST-1 to formazan was determined
using an ELISA reader (Bio-Tek, Bad Friedrichshall, Germany; 480
and 680 nm).
COLONY FORMATION ASSAY
For this long-term assay, 200–1600 cells/well were plated in 6-well
plates, incubated in normoxia for 24 h, and then treated with DHA
in normoxia or severe hypoxia. Plates seeded for treatment under
hypoxic conditions were transferred into the hypoxic chamber
2 h prior to DHA treatment until 24 h after treatment and subse-
quently incubated in normoxia. Plates were incubated for a total
of 10 days to allow growth of single colonies. Cells were then fixed
in 3.7% formaldehyde and 70% ethanol and subsequently stained
with 0.05% Coomassie Brilliant Blue. Colonies (≥50 cells/colony)
were counted under the microscope at fivefold magnification. The
survival curves were established by plotting the log of the surviv-
ing fraction against the treatment dose. Fitting of the curves was
performed using Excel software.
ANALYSIS OF APOPTOTIC AND NECROTIC CELL DEATH BY
FLUORESCENCE MICROSCOPY
Changes in nuclear morphology indicative for apoptosis and
necrosis were analyzed by fluorescence microscopy (Zeiss Axiovert
200,Carl Zeiss,Göttingen,Germany; G365/FT395/LP420 filter set)
upon cell staining with 1.5µM Hoechst 33342 and 2.5µg/ml PI.
Apoptotic and necrotic cells were quantified by counting the rela-
tive amount of fragmented blue or red nuclei (early or late apop-
tosis, respectively) and non-fragmented red nuclei (necrosis). At
least 100 cells were quantified in three independent fields per well.
FLOW CYTOMETRY ANALYSES
For quantification of apoptotic DNA-fragmentation (sub-G1 pop-
ulation), cells were incubated for 60 min with a staining solu-
tion containing 0.1% (w/v) sodium citrate, 50µg/ml PI, and
0.05% (v/v) Triton X-100 (v/v) and subsequently analyzed by
flow cytometry (FACS Calibur, Becton Dickinson, Heidelberg,
Germany; FL-2).
Dissipation of the ∆Ψm was measured using the ∆Ψm-
specific dye TMRE (FL-2) as described elsewhere (17).
To ensure a complete dissipation of ∆Ψm, cells were
treated with 100µM protonophore carbonyl cyanide m-
chlorophenylhydrazone (CCCP) before incubation with TMRE.
To quantify ROS production, cells were stained for 15 min at
37°C with 5µM of the ROS-sensitive dye DHE (Molecular Probes,
MoBiTec, Göttingen, Germany) and washed subsequently once
with PBS. ROS-positive cells were detected by flow cytometry (FL-
2). Treatment with 250µM H2O2 (2 h) was used as positive control
for ROS formation. As additional control, cells were pretreated
with 2 mM N -acetylcysteine (Acc) to block ROS formation.
Activation of Bax was determined using the activation-specific
anti-Bax NT antibody. In brief, cells were fixed for 20 min on ice
in 2.5% (w/v) PFA/PBS, washed in 1% (v/v) FCS/PBS, permeabi-
lized for 30 min on ice with 0.1% (v/v) Triton X-100/PBS, washed
with PBS, and then incubated for 15 min at room temperature
(RT) with a blocking solution (10% FCS/PBS). Cells were stained
for 30 min with the activation-specific anti-Bax NT antibody
or the respective isotype control, washed, incubated for 30 min
with a cy2-conjugated anti-rabbit secondary antibody (Amer-
sham, Freiburg, Germany), washed again, and then suspended in
blocking buffer for flow cytometric analysis (FL-1).
RELEASE OF CYTOCHROME C
Cells were plated on cover slips, washed with PBS, and fixed
for 15 min with 3% (v/v) paraformaldehyde in PBS at RT. Sub-
sequently, cells were permeabilized for 10 min with 0.2% (v/v)
Triton X-100 in PBS, washed with PBS, blocked for 30 min in 1%
(v/v) fetal calf serum, and subsequently incubated for 1 h at RT
with the anti-cytochrome c primary antibody (Pharmingen, Bec-
ton Dickinson). After repeated washing, cells were incubated for
45 min at RT in the dark with the secondary Cy2-conjugated anti-
mouse antibody (Amersham, Freiburg, Germany). Finally, the
cover slips were mounted with Fluorescence Mounting Medium
(Dako, Hamburg, Germany). Cytochrome c release was visualized
by fluorescence microscopy using a Zeiss Axiovert 200 microscope
equipped with an Apotome with an 63× oil objective and GFP fil-
ter set (Carl Zeiss, Jena, Germany). Analysis of green fluorescence
and overlay were performed with AxioVision software (Carl Zeiss,
Jena, Germany).
WESTERN BLOT ANALYSIS
Cells were lysed for 10 min at 99°C in 62.5 mM Tris-HCl (pH
6.8), 2% (w/v) SDS, 10% (v/v) glycerol, 50 mM dithiothreitol, and
0.01% (w/v) bromophenol blue. Proteins were separated by SDS-
PAGE and blotted onto PVDF-membranes (Roth, Karlsruhe, Ger-
many). After blocking with 5% (w/v) non-fat dry milk,membranes
were incubated at 4°C over night with the respective primary anti-
body (1:20,000 for β-actin, 1:1000 for all other antibodies). After
washing, the membranes were incubated for 1 h at RT with the sec-
ondary antibody (anti-IgG-HRP 1:2000, Amersham-Biosciences,
Freiburg, Germany), washed again, and developed using enhanced
chemiluminescence staining (ECL western blotting analysis sys-
tem, Amersham-Biosciences, Freiburg, Germany). We indicated
that protein levels were quantified by densitometry using ImageJ
software (ImageJ 1.40g, NIH, USA). The respective protein levels
were normalized to β-actin levels.
STATISTICS
Data represent mean values of at least three independent experi-
ments± standard deviation (SD). Specific values represent nor-
malization to respective solvent controls [% treated cells−%
solvent control]. Data analysis was performed by two-tail unpaired
t -test (Prism5™ software, GraphPad Inc., La Jolla, CA, USA)
or two-way ANOVA test using parametric methods and employ-
ing Bonferroni multiple comparison post-test where appropriate.
P-values ≤0.05 were considered as significant.
RESULTS
DIHYDROARTEMISININ EXERTS POTENT ANTI-NEOPLASTIC EFFECTS
UNDER NORMOXIC AND HYPOXIC CONDITIONS
To characterize the anti-neoplastic potential of DHA in severely
hypoxic cancer cells, we first compared tumor cell survival after
treatment with DHA under normoxic and under severely hypoxic
conditions. For this, we treated three different human colon cancer
cells (HCT15, Colo205, and HCT116 cells) with 0–80µM DHA
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for 48 h in the presence of normal (21% O2) or greatly reduced
oxygen tensions (0.2% O2). DHA significantly reduced the num-
ber of viable HCT15, HCT116, and Colo 205 colon cancer cells in
a concentration-dependent manner under normoxic (Figure 1,
upper panel) as well as under hypoxic conditions (Figure 1,
lower panel). The response of the three cell lines to DHA dif-
fered slightly depending on the drug concentration and the oxygen
levels. Whereas HCT15 cells turned out to be highly sensitive in
normoxia and hypoxia with almost 50% reduction in the num-
ber of viable cells upon treatment with 10µM DHA under both
conditions, the sensitivity of HCT116 cells was higher in hypoxia
(almost 50% reduction in the number of viable cells with 10µM
DHA compared to 20% in normoxia). In contrast, the number
of viable cells decreased only by around 20% in Colo205 upon
treatment with 10µM DHA under both, normoxic and hypoxic
conditions. Nevertheless, the results indicate that DHA is highly
active in normoxic and hypoxic colorectal cancer cells.
To characterize the mechanism of cytotoxicity more closely,
the mode of cell death induced by DHA was analyzed. For this
purpose, the three colon cancer cell lines were treated with 0–
50µM DHA under normoxic and hypoxic conditions. Forty-eight
hours later, the cells were co-stained with the membrane perme-
able DNA dye Hoechst 33342 and PI, a DNA dye that cannot
enter cells with intact plasma membrane integrity, to distinguish
between apoptotic and necrotic cell death (Figure 2A). PI-negative
and PI-positive cells with condensed DNA were mainly observed
after treatment with 25µM DHA under normoxia or hypoxia indi-
cating that at this applied concentration the dominant mode of cell
death was apoptosis (Figures 2B–D, left panels). In contrast, treat-
ment with 50µM DHA yielded elevated levels of PI-positive cells
without DNA condensation suggesting that necrotic cell death
was increased in response to treatment with higher DHA con-
centrations (Figures 2B–D, right panels). However, the impact
of normoxia or hypoxia on DHA-induced necrosis is not clear.
Whereas DHA-induced necrosis was much higher in normoxic
than in hypoxic HCT15 and HCT116 cells, Colo205 cells showed
more necrosis upon DHA treatment in hypoxia compared to
normoxia.
FIGURE 1 | DHA exerts potent anti-neoplastic effects on colon cancer
cells in normoxia and severe hypoxia. HCT15, Colo205, and HCT116 colon
cancer cells were treated for 48 h with various concentrations of DHA
(0–80µM) under normoxic (21% O2; black bars) or severely hypoxic
conditions (0.2% O2; white bars) as indicated. Cell proliferation and survival
were monitored 48 h after treatment by using the WST-1 assay that
quantifies the metabolic activity of viable cells. Ethanol (0.1%) was used as
solvent control. DHA reduces the number of viable HCT15, HCT116, and
Colo 205 cells in a concentration-dependent manner in normoxia (upper
panel) and hypoxia (lower panel). DHA displays almost similar anti-neoplastic
activity in normoxia and hypoxia. Data represent means±SD (n=3). Values
were normalized to the ethanol control. P -values were calculated applying
unpaired two-tailed t -test. *P <0.05; **P <0.01; ***P <0.001. Nx,
normoxia; Hx, hypoxia.
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FIGURE 2 | DHA induces apoptotic and necrotic cell death in colon
cancer cells in normoxia and hypoxia. HCT15, Colo 205, and HCT116 cells
were treated for 24 h with solvent (Ethanol, 0µM DHA) or DHA (25, 50µM)
under normoxic (21% O2; black bars) or under severely hypoxic conditions
(0.2% O2; white bars). To visualize apoptotic and necrotic cell death, cells
were stained with Hoechst (blue) and PI (red) and submitted to fluorescence
microscopy 24 h post treatment. (A) Representative fluorescence microscopy
pictures from one of three independent experiments are shown. Scale bar
corresponds to 100µm. Pictures were taken using 10-fold magnification.
(B–D) At concentrations of 25µM and below, DHA preferentially induced
apoptosis, whereas at 50µM DHA necrosis became more prominent. The
percentage of apoptotic and necrotic cells in (B) HCT15 cells, (C) Colo 205
cells, and (D) HCT116 cells was quantified by counting the fraction of cells
with normal, apoptotic, and necrotic nuclei using fluorescence microscopy
(DAPI channel). At least 100 cells per field were quantified from three
independent areas per condition. Data represent means from three
independent experiments±SD. Statistical analysis was performed according
to unpaired two-tailed t -test. *P <0.05; **, ##P <0.01, ***, ###P <0.001.
*Indicates the significance between the solvent treated control cells and
DHA-treated cells either in normoxia or hypoxia, # indicates the significance
between normoxic and hypoxic cells treated with the same concentration
of DHA.
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Taken together, our results indicate that DHA displays cyto-
toxic activity in colon cancer cells under normoxic and hypoxic
conditions.
EFFECT OF DIHYDROARTEMISININ ON SHORT-TERM AND LONG-TERM
CELL VIABILITY IN HCT116 CELLS
Although DHA induced cell death in colon cancer cells, the drug
also might affect the cell proliferation rate. Thus, we analyzed
the amount of viable HCT116 cells in a short-term assay mea-
suring the number of viable cells 48 h after treatment with DHA
(Figure 3A) as well as in a long-term assay measuring the surviv-
ing fraction in response to DHA (Figure 3B) under normoxic or
hypoxic conditions. Under normoxia, the number of living cells
was significantly reduced 48 h after treatment with 12.5 or 25µM
DHA. In hypoxia, the number of living cells was already slightly
decreased without treatment and was further lowered by treatment
with DHA, however, not to the same extent as under normoxic
conditions. On the other hand, the long-term assay showed that the
number of surviving cells able to regrow and form a colony declines
with increasing DHA concentration. Surprisingly, DHA treatment
reduced the surviving fraction even slightly more efficiently under
hypoxic conditions when compared to normoxic conditions. Our
results indicate that the long-term toxicity of DHA is slightly
improved under hypoxia as compared to normoxia, though the
number of surviving cells was slightly higher after short-term
treatment under hypoxic conditions. The results suggest that DHA
exerts pronounced long-term anti-neoplastic effects that enhance
clonogenic cell death particularly under hypoxic conditions.
DEPRIVATION OF OXYGEN RESULTS IN A SWITCH FROM
CASPASE-DEPENDENT APOPTOSIS TO CASPASE-INDEPENDENT
APOPTOSIS IN RESPONSE TO DIHYDROARTEMISININ
Earlier investigations in Jurkat T-lymphoma cells had demon-
strated that, under standard normoxic culture conditions, DHA
activates the intrinsic apoptosis pathway to trigger ROS-dependent
cell death (11). Intrinsic apoptosis is characterized by the acti-
vation of the Bcl-2 effector proteins Bax and/or Bak which,
in turn, induce the permeabilization of the outer mitochon-
drial membrane and cytochrome c release from the mito-
chondrial intermembrane space into the cytosol, which acts
as a co-factor to activate the caspase cascade [for review see
Ref. (18)]. This ultimately results in dissipation of the ∆Ψm
and DNA-fragmentation. To gain insight into the regulation
of DHA-induced cell death in HCT116 cells under normoxic
and hypoxic conditions, we compared the canonical steps of
the intrinsic apoptosis pathway in HCT116 cells in response to
DHA at 21 and 0.2% O2 (Figure 4). In normoxia, DHA read-
ily induced Bax-activation (Figure 4A), cytochrome c release
into the cytosol (Figure 4B), and cleavage of caspase-3 and
of the caspase-3 substrate PARP (Figure 4C), dissipation of
∆Ψm (Figure 4F), and DNA-fragmentation (Figure 4G), respec-
tively. Though Bax-activation was detected to a similar extent
upon DHA treatment under hypoxic conditions, cytochrome c
release into the cytosol, caspase-3 activation, and PARP-cleavage
were abrogated under these conditions. In addition, blocking
caspase-activation by co-treatment with pan-caspase inhibitor
zVAD-fmk and DHA under normoxia prevented cleavage of
caspase-3 and PARP (Figure 4D) as well as DNA-fragmentation
(Figure 4E), suggesting that the canonical apoptosis pathway is
activated in response to treatment with DHA under normoxic
conditions.
Interestingly, mitochondrial dissipation (Figure 4F) and DNA-
fragmentation (Figure 4G) were only slightly reduced in hypoxic
cells in response to treatment with 25µM DHA when com-
pared to treatment under normoxic conditions. Thus, our results
suggest that, in response to DHA, a caspase-independent apop-
totic cell death occurred when cells were treated under hypoxic
conditions.
FIGURE 3 | DHA reduces cell survival and eradicates clonogenic
tumor cells in normoxia and hypoxia. (A) HCT116 cell were treated
with DHA (12.5, 25µM) or with ethanol (solvent control, 0µM DHA).
Forty-eight hours later, living cells were counted using trypan blue
exclusion dye. P -values were calculated applying unpaired two-tailed
t -test; *P <0.05. DHA significantly reduced the number of viable cells
under normoxic conditions, but only slightly decreased the number of
viable cells under hypoxic conditions. (B) HCT116 cells were plated for
colony formation assay, treated 24 h later for 24 h with 0–20µM DHA
under normoxic (21% O2) or hypoxic conditions (0.2% O2) and
subsequently further incubated at 21% O2 for additional 10 days. Values
were normalized to the plating efficiency of the cells treated with
ethanol (0µM DHA). Data show the surviving fractions (SF) from three
independent experiments (means±SD). DHA-induced eradication of
clonogenic tumor cells was slightly better under hypoxic than under
normoxic conditions.
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FIGURE 4 | DHA induces caspase-dependent apoptosis in normoxia
but a caspase-independent apoptotic cell death in hypoxia. HCT116
cells were treated for 12–48 h under normoxic and hypoxic conditions
with solvent control (0µM), 12.5 or 25µM DHA as indicated.
(A) DHA-induced Bax-activation is similar in normoxia and hypoxia.
Bax-activation was monitored by flow cytometry 12 h after treatment
using an activation-specific anti-Bax antibody. (B) DHA induces significant
release of cytochrome c only in normoxia. Cytochrome c release was
visualized 12 h after DHA treatment by immunofluorescence (Zeiss Cell
Observer fluorescence microscope with Apotome; Axiocam MRm
camera; GFP filter). Scale bar corresponds to 10µm. Data show
representative pictures from three independent experiments.
(C,D) Activation of caspase-3 and cleavage of caspase-3 substrate PARP
were analyzed by western blotting at 24 h after treatment with DHA. Data
are representative blots out of three independent experiments.
(C) DHA-induced caspase-activation is abrogated in hypoxia. Caspase-3
activation (D) and DNA-fragmentation (E) can be blocked by co-treatment
with the pan-caspase inhibitor zVAD-fmk under normoxic conditions.
DHA induces depolarization of the mitochondrial membrane potential
[∆Ψm, (F)] and DNA-fragmentation [sub-G1, (G)] in normoxia and
hypoxia. Depolarization of ∆Ψm (F) and DNA-fragmentation (G) were
determined at 24 h after treatment by flow cytometry. (A,E–G) Data
represent means±SD from at least three independent experiments.
P -values were calculated applying unpaired two-tailed t -test; *P <0.05;
**, ##P <0.01; ***P <0.001. *Indicates the significance between the
solvent-treated control cells and DHA-treated cells either in normoxia or
hypoxia, # indicates the significance between normoxic and hypoxic cells
treated with the same concentration of DHA.
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DIHYDROARTEMISININ-INDUCED ROS PRODUCTION CONTRIBUTES TO
THE CYTOTOXIC EFFECTS UNDER NORMOXIC AND HYPOXIC
CONDITIONS
Earlier reports including own data pointed to ROS-dependent
induction of apoptosis by DHA and related compounds (11,
15, 16). Therefore, we next examined whether treatment with
DHA would increase cellular ROS levels in HCT116 cells and
whether DHA-induced apoptosis was ROS-dependent. As shown
in Figure 5A, the amount of ROS-positive cells increased in
response to treatment with DHA in a concentration-dependent
manner under both, normoxic and hypoxic conditions. How-
ever, ROS production was significantly lower when treatment was
performed in severe hypoxia. Moreover, pre-treatment with the
radical scavenger Acc not only decreased DHA-induced ROS pro-
duction (Figure 5A), but concurrently decreased DHA-induced
DNA-fragmentation under normoxic and hypoxic conditions
(Figure 5B). These observations demonstrate that the induction of
ROS is essential for the cytotoxic action of DHA in both treatment
conditions.
NORMOXIC AND HYPOXIC HCT116 CELLS UP-REGULATE DIFFERENT
SETS OF BH3-ONLY PROTEINS UNDER NORMOXIC AND HYPOXIC
CONDITIONS
Since activation of Bax seems to be an important step during
DHA-induced cell death under normoxic and hypoxic conditions,
a western blot analysis was performed to examine whether a change
in the expression of other Bcl-2 family members could contribute
to apoptosis induction (Figure 6). HCT116 cells express higher
levels of Bax than the closely related Bak as well as higher levels
of the anti-apoptotic Bcl-xL than the closely related protective
Bcl-2. However, the expression of these four proteins was not
affected by DHA. In contrast, treatment with DHA resulted in
slightly increased levels of the anti-apoptotic Mcl-1, although
Mcl-1 levels were lower when cells were cultured in hypoxic con-
dition as compared to normoxic conditions. Interestingly, the
pro-apoptotic BH3-only protein Noxa showed similar regulation
like its interacting partner Mcl-1.
In contrast, levels of the BH3-only proteins Bim and Puma were
only elevated in response to treatment with DHA when treatment
was performed under normoxic conditions. Instead, expression
of the BH3-only protein BNIP3 was up-regulated when HCT116
cells were exposed to severe hypoxia and its levels further increased
after DHA treatment though BNIP3 was not detected in normoxia.
Taken together, our data suggest that different sets of BH3-only
proteins are up-regulated in response to DHA under normoxic
and hypoxic conditions.
BNIP3 is known to interact with Bcl-2 thereby counteracting
Bcl-2’s anti-apoptotic activity or preventing Bcl-2 from binding
to Beclin-1. The former interaction results in apoptosis induc-
tion whereas the latter one results in autophagy induction. In
addition, autophagy-associated cell death might also contribute
to clonogenic cell death. Therefore, we examined the induction
of autophagy by analyzing LC3B processing to a 14 kDa form in
HCT116 cells. Interestingly, an increase of the 14 kDa LC3B band
was observed under normoxic conditions when BNIP3 expres-
sion was hardly detectable. In contrast, under hypoxic condi-
tions, no increase of processed LC3B could be detected although
BNIP3 levels were dramatically increased. Thus, our results sug-
gest that BNIP3 does not regulate autophagy but rather apoptosis
in hypoxic HCT116 cells.
FIGURE 5 | ROS are important mediators of DHA-induced cytotoxicity in
both, normoxia and hypoxia. (A,B) HCT116 cells were pre-incubated for
30 min in the absence or presence of the radical scavenger N -acetylcystein
(Acc; 2 mM) and then treated for 24 h (A) or 48 h (B) with DHA (0–25µM)
under normoxic and hypoxic conditions as indicated. (A) DHA induces ROS
under normoxic and hypoxic conditions in a concentration-dependent manner.
Treatment with 250µM H2O2 for 2 h was applied as a positive control for ROS
formation. Pre-treatment with the ROS scavenger N -acetylcystein (Acc) was
used to intercept and neutralize ROS. ROS formation was detected by flow
cytometry upon loading of the cells with the oxidation-sensitive dye DHE.
(B) DHA-induced DNA-fragmentation is ROS-dependent in normoxia and
hypoxia. DNA-fragmentation (sub-G1) was analyzed by flow cytometry after
staining the cells with PI. Data represent means±SD from three
independent experiments. P -values were calculated applying unpaired
two-tailed t -test. *, #P <0.05; **, ##P <0.01; ***P <0.001. *Indicates the
significance between the solvent-treated control cells and DHA-treated cells
either in normoxia or hypoxia, # indicates the significance between normoxic
and hypoxic cells treated with the same concentration of DHA.
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FIGURE 6 | BH3-only proteins Bim, Puma, Noxa, and BNIP3 are
differentially regulated in response DHA in normoxia and hypoxia.
HCT116 cells were treated with 0, 12.5, or 25µM DHA under normoxic or
under hypoxic conditions as indicated. Twenty-four hours later, whole cell
lysates were made. Levels of anti-apoptotic and pro-apoptotic proteins of
the Bcl-2 family were analyzed by western blot. Induction of autophagy was
accessed by western blot using an antibody against LC3B and a
subsequent analysis of processed LC3B form (LC3B II, 14 kDa). Levels of
anti-apoptotic Bcl-2 and Bcl-xL and pro-apoptotic Bax and Bak did not
change in response to treatment with DHA under normoxic and hypoxic
conditions. Levels of BH3-only protein Noxa were increased in response to
DHA in normoxia as well as in hypoxia. Levels of Bim and Puma were only
increased by DHA in normoxia, whereas levels of BNIP3 were elevated by
DHA only in hypoxia. Induction of autophagy in response to DHA was
observed only under normoxic conditions. Protein levels were analyzed by
densitometry and normalized to β-actin levels. Relative protein levels are
shown below the respective blots. Data show representative blots from at
least two independent experiments.
DISCUSSION
Hypoxia is a major biological factor that limits the success of anti-
cancer treatment. Here, we demonstrate for the first time that the
anti-neoplastic cyclic endoperoxide DHA is a hypoxia-active anti-
cancer drug that efficiently eradicates colon cancer cells not only
under normoxic conditions but also when treatment is performed
in a severely hypoxic microenvironment.
ANTI-NEOPLASTIC ACTIVITY IN NORMOXIA AND HYPOXIA
Under normoxic conditions, DHA potently induced cell death,
particularly apoptosis, in colon cancer cells whereas necrotic cell
death was only induced to a substantial extent when rather high
drug concentrations were used.
The main mode of DHA-induced cell death in colon cancer
cells under hypoxic conditions also resembled apoptosis. This
assumption is based on the findings that dissipation of the mito-
chondrial membrane potential as well as DNA-fragmentation were
still observed in severe hypoxia, though caspase-3 activation was
greatly reduced. This is reminiscent of a caspase-independent
apoptosis with DNA-fragmentation that was described before
(19). In this context, previous publications suggested a translo-
cation of apoptosis-inducing factor (AIF) and endonuclease G
(EndoG) from mitochondria to the nucleus, where both proteins
are able to initiate DNA-degradation independent of caspase-
activation (20, 21). The pronounced sensitivity to DHA-induced
apoptosis observed in short-term assays strongly correlated with
efficient eradication of clonogenic HCT116 cells in long-term
colony formation assays. Notably, the drug displayed even slightly
higher activity in HCT116 cells treated under severely hypoxic
conditions.
POTENTIAL OF DHA IN ANTI-CANCER THERAPIES
A hypoxic microenvironment renders cancer cells resistant to
most standard anti-cancer therapies and, thus, constitutes a major
obstacle in the treatment of cancer patients (2). The molecu-
lar mechanisms leading to the increased resistance of hypoxic
cancer cells to standard chemotherapeutic drugs or ionizing radi-
ation are not fully understood. However, previous publications
have demonstrated that hypoxic tumor cells stabilize the hypoxia-
inducing factor-1α (HIF-1α) leading to the HIF-1α-dependent cell
protection, increased transcription of vascular endothelial factor
(VEGF), and tumor vessel formation (3, 22). There is increas-
ing evidence that DHA interferes with HIF-1α activation, VEGF
expression, and angiogenesis. On the one hand, DHA treatment
reduced hypoxia-induced HIF-1α activation and VEGF expres-
sion in multiple myeloma and C6 rat glioma cells resulting in
reduced tumor cell growth and angiogenesis, respectively (23, 24).
On the other hand, DHA enhanced the toxicity of cisplatinum
in lung adenocarcinoma cells in vivo and this effect was accom-
panied by reduced expression of HIF-1α and VEGF and reduced
tumor microvessel density (25). Interestingly, this anti-angiogenic
effect of DHA was attributed to growth inhibition of endothelial
cells and depended on the level of tissue oxygenation and the drug
concentration (26). Thus, the anti-angiogenic effects described
above differ from our findings where DHA was almost similarly
active under normoxic and hypoxic conditions in all three colon
cancer cell lines examined (see Figure 1). The pronounced activ-
ity of DHA in severe hypoxia suggests that the drug has a great
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advantage over many standard anti-cancer drugs and radiotherapy
whose cytotoxic effects strongly rely on adequate oxygen tensions
as well as on intact cell death pathways (7, 27).
Moreover, although not yet examined in clinical trials, DHA is
able to improve treatment efficacy in combination with ionizing
radiation or cisplatin in preclinical models (25, 28, 29) and thus
shows great potential as anti-neoplastic drug.
Of note, drug concentrations used in the present study corre-
spond to DHA plasma levels achievable in humans. Upon repeated
intravenous application of 8 mg/kg artesunate, peak plasma con-
centrations up to 5.8 mg/l (around 20µM) of its principal active
metabolite DHA were measured in healthy volunteers (30).
GENERATION OF ROS IN RESPONSE TO DHA
Up to now, preclinical studies about the anti-neoplastic activity of
artemisinin and derivatives had been mostly restricted to exper-
iments conducted in normoxia. These studies demonstrated that
the cytotoxic action of these compounds involves the formation of
ROS and membrane oxidation upstream of apoptosis-associated
changes in mitochondrial function (11, 31, 32). Moreover, chronic
treatment of LN-229 glioblastoma cells with artesunate led to a
continuous increase in ROS and in oxidative DNA-damage result-
ing in continuously increasing DNA double-strand breaks and
finally tumor cell death (16).
Our present data show for the first time that DHA can induce
ROS formation in hypoxia, though at slightly reduced levels. The
generated ROS were important mediators of DHA-induced cyto-
toxicity under normoxic as well as under hypoxic conditions since
blocking ROS formation by Acc resulted in abrogation cell death
under normoxic or hypoxic conditions. Although DHA-induced
oxidative DNA-damage and the resulting DNA-damage response
have not been studied here, it is highly likely that treatment with
DHA under normoxic as well as under hypoxic conditions will
also result in the generation of DNA double-strand breaks and,
finally, in cell death due to the inability of the cells to repair the
damaged DNA.
Taken together, our novel data indicate that the generation of
ROS is a hallmark of DHA-induced cell death under normoxic as
well as under hypoxic conditions.
ROLE OF BCL-2 FAMILY MEMBERS FOR THE REGULATION OF
DHA-INDUCED CLONOGENIC DEATH IN HYPOXIA
The effector proteins of the Bcl-2 protein family, Bax and Bak, are
essential for apoptosis induction. Both of them become activated
in response to many apoptotic stimuli (11, 33–35). In addition,
up-regulation of Bax levels was detected in response to cere-
bral ischemia or following exposure to ionizing radiation in a
p53-dependent way (36–38). Although the levels of pro-apoptotic
proteins Bax and Bak were not changed in response to treatment
with DHA, their activation might be essential for DHA-induced
cell death. Indeed, Bax was activated in most HCT116 cells after
treatment with DHA under normoxia and hypoxia. Thus, the
results suggest, that at least Bax might be a very important media-
tor of DHA-induced cytotoxicity under normoxic as well as under
hypoxic conditions.
Furthermore, anti-apoptotic proteins of the Bcl-2 family par-
ticipate in the regulation of the balance between apoptosis and
autophagy in response to cell stress, including hypoxia (39, 40).
They associate either with Bax or Bak to prevent outer mito-
chondrial membrane permeabilization and apoptosis induction
or with Beclin-1 preventing this molecule from induction of
autophagy (18, 41–45). Both, apoptosis and autophagy could
contribute to clonogenic cell death induced by DHA. However,
Bcl-2 or Bcl-xL levels did not change in response to DHA treat-
ment under normoxic or hypoxic conditions. Only Mcl-1 levels
were decreased when cells were grown under hypoxia. Treat-
ment with DHA slightly increased Mcl-1 levels under hypoxia,
but had no effect under normoxia. Yet, the three protective pro-
teins can be released from a complex formed with Bax/Bak or
Beclin-1 by a competitive interaction with BH3-only proteins such
as Bim, Puma, Noxa, and BNIP3. Interestingly, Noxa levels were
increased in response to DHA under normoxia as well as hypoxia.
In contrast, Bim and Puma levels were up-regulated only under
normoxic conditions, whereas BNIP3 levels were increased only
under hypoxic conditions after treatment with DHA. Further-
more, previous publications have shown that BNIP3 up-regulation
was observed preferentially in hypoxic cells and was often asso-
ciated with autophagy induction due to the release of Beclin-
1 from interaction with Bcl-2 or Bcl-xL by replacement (46).
However, BNIP3 is also able to induce apoptosis by binding to
Bcl-2 and Bcl-xL (47). Surprisingly, autophagy induction as mea-
sured by LC3B processing was detected only in normoxic cells
in response to DHA treatment in the absence of BNIP3. In con-
trast, under hypoxia, when BNIP3 levels were greatly increased,
processing of LC3B could not be detected. Thus, our data sug-
gest that BNIP3 regulates rather apoptosis than autophagy under
hypoxic conditions. However, up-regulation of the BH3-only
proteins, Bim and Puma could result in an enhanced inter-
action with Bcl-2 and Bcl-xL to induce both, autophagy and
apoptosis, under normoxic conditions. Taken together, our data
clearly demonstrate a differential expression of BH3-only proteins
under normoxic and hypoxic conditions in response to treatment
with DHA in HCT116 colon cancer cells to induce cancer cell
death.
Given that we did not analyze the protein complexes in more
detail, we cannot state whether the discussed BH3-only proteins
associate with the anti-apoptotic Bcl-2 members to release Beclin-
1 and induce autophagy or to activate Bax and Bak to induce
apoptosis. A further analysis of Bcl-2, Bcl-xL, and Mcl-1 as well as
their interacting partners will clarify the molecular mechanisms
by which DHA induces apoptosis and autophagy under normoxic
and hypoxic conditions.
CONCLUSION
In contrast to many genotoxic drugs and radiotherapy, which are
generally less efficient in hypoxic tumor cells, DHA exerts pro-
nounced anti-neoplastic effects under severely hypoxic conditions.
While the canonical intrinsic apoptosis pathway seemed to be pre-
dominantly activated by DHA in oxygenated cells, DHA induced
a caspase-independent apoptosis-like cell death in severe hypoxia.
Since DHA targets normoxic as well as hypoxic cells with equal
potency, the drug might be a promising tool to improve treat-
ment outcome, particularly in hypoxic human tumors resistant to
conventional therapies.
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